Ikarian Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ikarian Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-110,000	Closed	-$11.2M	–	178
2023 Q2	$11.2M	Buy	110,000 +10,000	+10%	+$946K	1.79%	18
2023 Q1	$9.09M	Buy	+100,000	New	+$5.87M	2.06%	12
2022 Q4	–	Sell	-138,100	Closed	-$3.47M	–	112
2022 Q3	$3.47M	Sell	138,100 -23,900	-15%	-$662K	0.69%	46
2022 Q2	$4.92M	Buy	162,000 +146,700	+959%	+$4.38M	0.9%	36
2022 Q1	$502K	Sell	15,300 -184,700	-92%	-$5.48M	0.07%	138
2021 Q4	$5.27M	Buy	200,000 +90,400	+82%	+$7M	0.79%	32
2021 Q3	$11M	Buy	+109,600	New	+$12.8M	0.78%	34
2020 Q4	–	Sell	-117,100	Closed	-$11.4M	–	258
2020 Q3	$11.4M	Sell	117,100 -50,000	-30%	-$6.25M	0.83%	32
2020 Q2	$26.1M	Buy	+167,100	New	+$25.4M	2.07%	7

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ikarian Capital's RETA Position: Q3 2023 in Review

Ikarian Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,472 shares — an estimated $558K sold.

Ikarian Capital first reported a position in RETA in Q1 2021 and held it in 6 quarters. The position peaked at $7.32M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Ikarian Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 5,472 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $558K.
Ikarian Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 6 quarters.
Ikarian Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.32M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.